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Abstract: The interaction of [VO(acac)2] with 2,6-bis(hydroxymethyl)-4-methylphenol (L1H3) or 6,6/-
methylenebis(4-tert-butyl-2-(hydroxymethyl)phenol) (L2H4) in refluxing toluene afforded, following 
work-up in ethanol, the complexes [VOL1]2 (1) and {[VO(acac)(HOEt)](VO)L2]}2 (2), respectively. 
Use of 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid (L3H2) or 4-[3,5-bis(2-
hydroxyphenyl)-1,2,4-triazol-1-yl]benzosulfonic acid (L4H2) with [VOCl3] in refluxing acetonitrile, 
followed by methanol and THF work-up, afforded the complexes [Et3NH][VO(OMe)L3]2 (3) and 
[Et3NH][VO(OMe)L4]2 (4), respectively. The interaction of [VOSO4] and L3H2 in refluxing 
acetonitrile afforded, with extraction into methanol, the complex [VO(OMe)L3]2 (5). The molecular 
structures of 2, 3 and 5 have been determined; the structure of 1 has been reported previously. The 
complexes in this study have been determined to be of low toxicity using in vitro cell assays with 50% 
cytotoxicity values (CC50) values in the range 56 – 126 µM.  
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1. Introduction  
Coordination compounds of vanadium continue to attract attention given their potential applications 
in areas such as supramolecular chemistry, energy applications and catalysis including olefin 
polymerization, ring opening polymerization, and oxidation catalysis. [1] There is also much interest 
in their medicinal/biological properties, including as insulin mimics, and a number of reviews have 
appeared over the last couple of decades. [2] In the field of metal-based (non-Pt) anti-cancer agents, 
a number of early transition metal systems have shown promise. [3,4] It is desirable that the metals 
employed are both earth abundant and cheap. With this in mind, we note that vanadium complexes 
have been shown collectively to possess a number of the essential effects on cancerous cells required 
for an effective anti-cancer agent, either solely or in combination with other anti-cancer agents. [5] 
As an example, a series of peroxovanadium complexes have shown reduction in cellular growth rate 
in neuroblastoma NB41 and glioma C6 cell lines. [6] On the other hand, other peroxovanadates that 
form in C3H10T1 fibroblasts in situ have been shown to actually cause proliferation of cancerous 
cells. [7] Tests have shown that vanadium complexes block the G2 – M transition of the cell cycle, 
so mitosis never occurs. [6] Furthermore, vanadium complexes have been shown to induce protein 
tyrosine phosphorylation in a number key proteins that are linked to the production of highly 
reactive oxygen species that cause damage to DNA. [8-11] This causes an increase in the production 
in reactive oxygen species that eventually leads to cell necrosis. Vanadium has also been shown to 
inhibit phosphotyrosine phosphatases (PTPs), [12,13] which regulate signal transduction pathways 
causing apoptosis. [14,15]  
There are a few examples of organisms that have grown resistant to the effects of vanadium 
by altering the way in which they control protein tyrosine phosphorylation. [16] However in 
combination with other anti-cancer agents, vanadium has been shown to reverse drug resistance in 
a number of cancers. For example, sodium orthovanadate has been shown to re-sensitize CEM/VLB 
100 cells to vinblastine. [17] Furthermore, when vanadium is bound by a chelating agent, it actually 
reverses the resistance of human ovarian cancer cells to cisplatin, allowing the ‘gold-standard’ anti-
cancer treatment to destroy the cancerous cells. [18]  
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We note that Schiff base complexes of [VIVO]2+ have recently been screened against human 
tumour cell lines (HeLa and HCT-15), and, for some of the complexes, activities greater than 
cisplatin were observed. [19] Entry into this high-valent vanadium chemistry is via the use of the 
starting materials [VO(acac)2], [VOCl3] and [VOSO4]; the use of [VO(acac)2] has been reviewed. 
[20] Previously, we have noted promising cytotoxicity results using phenolic macrocycles 
(calixarenes) bearing oxidovanadium groups, [21] and we now report our results on a number of 
non-macrocyclic phenolic systems, see scheme 1. These include the deferasirox chelator (L3H2) for 
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Scheme 1. Oxidovanadium(IV and V)  compounds 1 - 5 studied herein.  
 
2. Results and Discussion  
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2.1 Synthesis and molecular structures 
The reaction of oxidovanadium(IV) acetylacetonate and 2,6-bis(hydroxymethyl)-4-methylphenol in an 
equal molar ratio in refluxing toluene over 2 h, following work-up, afforded a dark blue solution, from 
which on standing (24 h) under air (i.e. evaporation) red crystals formed in a yield of 65%. The structure 
of this red product was identified as the previously reported complex [VOL1]2 (1), [23] (see ESI, Fig. 
S1). Over time (6 – 8 weeks), the red product decomposed to a mud-brown colour, so batches of this 
complex are best kept in a glovebox until they are required for subsequent use. This decomposition 
process was determined by Chaudhury et al. [23] to be the formation of an oligomeric aldehyde-
coordinated vanadium(IV) complex. 
We note that use of the same pro-ligand, but with oxidovanadium(IV)  sulfate and varying quantities of 
triethylamine, results in similar binding of dioxovanadium(V) or oxovanadium(IV) groups as recently 
observed by Mikuriya et al. [24]; three different structures I, II, and III (see Scheme 2) were isolated 
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Scheme 2. Structural motifs I and II observed by Mikuriya et al. [24]  
 
 
The synthesis of tetra-nuclear 2 was carried out under anaerobic conditions. The pro-ligand 6,6/-
methylenebis(4-tert-butyl-2-(hydroxymethyl)phenol) (L2H4) was reacted with an excess of  
oxidovanadium(IV) acetylacetonate in refluxing toluene over 48 h. Following work-up (extraction into 
warm ethanol), tiny dark green crystals grew over the course of several weeks (in 24 % yield). Despite 
the weakly scattering nature of the crystals, it proved possible to obtain data of sufficient quality to 
identify the connectivity. A view of the molecule is shown in Figure 1, with alternative views provided 
in the ESI (Fig. S2). 
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Figure 1. Molecular structure of {[VO(acac)(HOEt)](VO)L2]}2  (2). Atoms labelled with the prime 
symbol are generated using the symmetry operation 1-x,-y, 1-z. 
 
The structure consists of two deprotonated pro-ligands L2 bridged by four vanadium atoms forming a 
centrosymmetric dimer of formula {[VO(acac)(HOEt)](VO)L2]}2 (2). The coordination environment at 
the outer, pseudo octahedral oxidovanadium centres is completed by an acac and an ethanol ligand; the 
V – O bond lengths of ca. 2.0 Å are longer than that observed in related ethoxide complexes (V – O 
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typically ca. 1.74 Å. [25] This is consistent with the presence a v(OH) at 3398 cm-1 in the IR spectrum; 
strong stretches at 1015 and 958 cm-1 are assigned to the v(V=O) groups. In the MALDI mass spectrum, 
the molecular ion is observed at 1292.12. The two inner oxidovanadium centres (V2/V2/) are 5-
coordinate and adopt distorted squared-based pyramidal geometries. The τ value here, which has been 
defined as the degree of trigonality, is 0.357, and this confirms here the geometry is close to square 
pyramidal rather than trigonal bipyramidal. [26] In terms of oxidation states, the observed ligation and 
charge balance is consistent with a mixed-valence system for which the inner oxidovanadium centres 
(V1/V1/) are V(IV) and the outer oxidovanadium centres are V(V).  
In the packing of 2, there are no classical hydrogen bonds between the molecules of 2 in the solid state. 
The crystal packing (see figure 2) involves assembly of the molecules in puckered sheets that extend in 
the xz plane. These sheets are stacked so as to generate channels that run through the structure parallel 
to the crystallographic a direction and these comprise 26 % of the crystal volume. These are filled with 
disordered solvent.  
 
Figure 2. Crystal packing of 2 shown along the a-direction. Channels parallel to a are clearly visible. 
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Again, the synthesis of 3 was carried out under anaerobic conditions. The triazole pro-ligand, L3H2, was 
suspended in acetonitrile and a slight excess (1.2 equivalents) of vanadium(V) oxytrichoride was added. 
After initial extraction into MeOH failed to yield crystals, a following work-up (extraction into THF) 
gave a dark blue/black solid, which was then taken up in THF. Standing for 48 h at -20°C afforded dark 
blue crystals of [Et3NH][VO(OMe)L3]2 (3) (65% yield). The related complex 4 was prepared in a similar 
manner using L4H2, in an isolated yield of 56%. In the IR spectra of 3 and 4, a strong stretch at 959 and 
962 cm-1, respectively is assigned to the v(V=O) groups. In the MALDI mass spectra, the molecular ion 
are observed at 875.99 and 948.03 for 3 and 4, respectively. 
Complex 3 crystallises in the space group Pc and the asymmetric unit comprises a single dimeric V 
complex (Figure 3) a molecule of methanol, one of water, one of diethylether, and a triethylammonium 
cation. The V complex has carboxyl groups at each end; statistically one of these is protonated (ie 
formally one is COOH and one is COO− at random). Each vanadium is coordinated by one nitrogen in 
the triazole ring and two deprotonated oxygens from phenol units in the pro-ligand L3H2. The 
coordination at each metal is completed by a methoxide ligand and an oxide forming an oxidovanadium 
group. The result is that both vanadium ions exhibit a distorted octahedral geometry; there is a long 
(2.334Å) V-O interaction to a phenoxide oxygen of a second L3 ligand, trans to the oxidovanadium, 
such that a dimer is formed (see Figure 3 V2-O1). Three additional non-coordinated methanol molecules 
and a single protonated triethylammonium unit complete the structure, the presence of the latter means 
that the dimeric anion must be of mixed valence, i.e. V(V) and V(IV). Details of the crystal structure 
can be found in Table 2. 
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Figure 3. Asymmetric unit of 3. Selected bond lengths (Å) and angles (o): V1=O3 1.593(9) Å, V1-
N1 2.102(10) Å, V1-O2 1.886(8) Å, V1-O1 1.955(8) Å, V1-O7 1.792(9) Å, V1-O5 2.333(9) Å, 
V2=O6 1.595(9) Å, V2-N4 2.128(10) Å, V2-O4 1.842(10) Å, V2-O5  1.954(9) Å, V2-O8  1.798(8) 
Å, V2-O1 2.299(9) Å. 
 
In 3, the carboxylic acid on one molecule forms a hydrogen bond to carboxylate on an adjacent 
molecule forming a COOH∙∙∙−OOC hydrogen bond. The very close approach of the two oxygen 
atoms (O∙∙∙O distance is 2.4554(1) Å) is consistent with this hydrogen bond. These classical 
hydrogen bonds link the complexes into tapes that run parallel to the [101] direction. Further non-
classical hydrogen bonds (C−H∙∙∙O) stack these tapes parallel to the a direction. In between the 
chains the ether, water, and triethylammonium cation for a hydrogen-bonded cluster. For a view of 
3 down the [010] direction, see Figure 4. 
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Figure 4: View of 3 down the [010] direction.  
 
 
The interaction of [VOSO4] and L3H2 in refluxing acetonitrile afforded, following extraction into 
methanol, the complex [VO(OMe)L3]2 (5). Given the nature of the ligands present, the 1H NMR 
spectrum of 5 mostly comprises of a complex aromatic region (see figure S5 for an expansion of 
this region), together with a single at δ 3.28 for the methoxides; the acid proton is assigned to a very 
broad resonance over the range 10.55 to 8.30 ppm (in the parent ligand, it appears as a broad singlet 
at c.a. 11.4 ppm in dmsod6). Light brown crystals of 5 suitable for an X-ray diffraction study were 
obtained via diffusion of CH2Cl2 and methanol. The molecular structure is shown in Figure 5, with 
selected bond lengths and angles given in the caption. 5 crystallises in the centrosymmetric space 
group P-1 with a half of one dimer and one molecule of methanol within the asymmetric unit. The 
oxidovanadium(V)  cation is coordinated by three atoms from the deprotonated phenolate and one 
molecule of methanol to give a distorted octahedral geometry about the metal. Each dimer is 
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generated by the centre of symmetry and the phenolate oxygen atoms bridge between two identical 
oxidovanadium(V) cations. These oxygen atoms form one short bond and one long bond to 
vanadium (V(1)—O(1) = 1.9498(12) and O(1)—V(1)i 2.3479(12) Å where i = 1−x, 1−y, 1−z). Each 
carboxylic acid is not deprotonated and this forms a hydrogen bond to unbound methanol. This 
hydrogen bonding sustains infinite chains formed from C44(12) embraces of two carboxylic acids 
bridge by two methanol molecules (See Fig. S3, ESI). 
 
Figure 5. Asymmetric unit of 5. Selected bond lengths (Å) and angles (o): V1—O1 = 1.9498(12) and 
O1—V1i 2.3479(12), V1—O2 = 1.8474(12), V1—O3 = 1.5963(13), V1—O4 = 1.7940(13), V1—N1 = 
2.1265(15); O1—V1—O2 = 153.05(6), N1—V1—O4 = 167.29(6), O1—V1—O3 = 96.67(6). 
 
In the packing of 5, the complex and methanol are involved in an extended hydrogen-bonded network 
in the solid state. The free carboxylic acid group of each complex is linked to another in an R44(12) 
embrace that involves two molecules of methanol, see figure 6. These interactions form tapes along the 
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[212] direction. Further C−H∙∙∙O interactions hold the tapes together in the solid to make a dense 
hydrogen-bonded array, see figure 7.  
 
Figure 6. The R44(12) embrace that forms hydrogen-bonded tapes within 5. Dashed lines show 
O−H∙∙∙O hydrogen bonds.  
 
 
Figure 7. Packing of 5 in the solid state. Structure is viewed down the c-axis. Dashed lines show 
O−H∙∙∙O hydrogen bonds.  
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2.2 EPR spectroscopy 
The EPR spectrum of the oxidized form of 1 has previously been reported. [23] In powdered form, 
tetramer 2 exhibited a broad EPR spectrum (due to intermolecular interactions; ESI, Fig. S5): the 51V 
hyperfine structure (51V, 99.8% natural abundance, nuclear spin I = 7/2) was partially resolved in the 
second derivative spectrum (Fig. S5). As a fluid CH2Cl2 solution, an 8-line hyperfine pattern was 
observed (ESI, Fig. S6) with Aiso = 295 MHz and giso = 1.973, consistent with a simple V(IV), d1  
oxidovanadium(IV) monomer and hence with the formulation of the dimer-of-dimer structures of 2 as 
{VIVVV}2 where the two dimers are well separated and non-interacting. On freezing, the solution a 
poorly resolved spectrum was found (figure 8, top), possibly due to poor glassing (or slight precipitation) 
in this solvent. Sharp and broad signals were observed, but again characteristic of a V(IV) 
oxidovanadium(IV) monomer. A clean spectrum was obtained on recording the second derivative (figure 
8, middle), and simulation (figure 8, bottom) gives axial g-values of gz = 1.945, gx,y = 1.980 with 51V 
hyperfine couplings of Az = 517, Ax,y = 190 MHz. These features match those from the powder spectrum 
(ESI, Fig. S7), consistent with similar structures in both phases.  
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Figure 8. EPR of 2 in CH2Cl2 solution at 130 K, presented as first (top) and second (middle) derivative 
spectra. Bottom: simulation of second derivative spectrum with the parameters in the text. 
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Figure 9. From top to bottom: experimental powder X-band EPR spectrum of 3 at room temperature 
(black; frequency = 9.4608 GHz) and simulation (red); experimental frozen CH2Cl2 solution X-band 
EPR spectrum at 150 K (black; frequency = 9.4776 GHz) and simulation (red). 
 
In the case of 3, spectra of powders at room temperature and frozen solution (figure 9, top) were well 
resolved and gave identical g and A values (gz = 1.952, gx,y = 1.983, Az = 490, Ax,y = 165 MHz), hence 
the structure is maintained in solution. The same is true for 4, giving very similar parameters of gz = 
1.950, gx,y = 1.982, Az = 495, Ax,y = 172 MHz. The hyperfine coupling constants for 3 and 4 are 
significantly smaller than those of 2: this is consistent with the VO4N vs. VO5 coordination spheres. The 
resolution of hyperfine to only one 51V nucleus is consistent with the V(IV)V(V) formulation above, and 
is reminiscent of the situation observed by Chakravorty et al for the complex Et4N[V2O3(L-asal)2]. 
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[27a] We also note that for the complex {[VVO(L)][VIVO(L)](µ-O)}-, where L is an aroylazine, it was 
invoked that the unpaired electron is extensively delocalized between the two V centers in the formed 
mixed-valence complex; a similar situation is very likely for 3 and 4. [27b]  
 
Figure 10. Room temperature X-band EPR spectrum (9.4526 GHz) of 3 as a CH2Cl2 solution. 
 
 
At room temperature the solution sample gives a fairly weak, but well resolved, 15-line hyperfine 
splitting pattern (figure 10). The hyperfine splitting are approximately half the value expected for a 
VO2+ monomer, which is what is expected from coupling to two equivalent I =7/2 nuclei (2nI + 1) 
as a result of exchange between the two vanadium ions. This confirms the dimeric structure in 
solution, however it is odd that this is not observed in the frozen solution or solid-state spectra. One 
possible explanation is that the exchange coupling is dependent of the temperature.  
 ©2019, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
The EPR spectra of vanadium complexes of biological relevance has been reviewed. [28] 
 
2.3 Cytotoxicity studies 
 In order to evaluate the biological activity of complexes 1–4, cell viability assays were 
performed. The complexes were tested for their anti-proliferative activity against human brain 
glioblastoma (U87) cells. A 72 h time point was selected to maximise the cytotoxic effect, this was 
considered in comparison with some previous literature studies where 16 h and 48 h time points were 
used, but showed lower activity with these shorter incubation times. [29] There is significant variation 
in the cytotoxicity results reported in the literature with different cell lines and assay time points used, 
see examples included in Table 1. 
The assay measurement was made after cells were incubated with the compounds for 72 h and is 
the result of the mitochondrial based reduction of a tetrazolium dye (MTS) to its formazan product. 
Different types of assays have previously been assessed for their relevance to determine biological 
activity profiles of vanadium complexes. [30] The CC50 values (molar amount of the complex required 
to reduce cell growth by 50%) were determined, see Table 1. The complexes synthesised give CC50 
values that range from 57 μM for 2 to 126 μM for 3 showing comparatively low cytotoxicity. 
The U87 cell line was selected due to the clinical importance of glioblastoma and the limited but 
promising data in the literature. [31] The most appropriate literature comparator compound for the U87 
cell line is bis(4,7-dimethyl-1,10 phenanthroline) sulfatooxovanadium(IV) (METVAN) which has been 
investigated using U87 models both in vitro and in vivo. METVAN exhibits low micromolar cytotoxicity 
in vitro and has been shown to reduce tumour growth in vivo for implanted U87 tumours in mice. 
  Previously, a series of different cell lines have been used to analyse vanadium salts (including 
oxidovanadium(IV) sulfate) and compounds that are available for human administration. [29] Using 
longer assay time points and variation in cell lines, common vanadium salts can show potent cytotoxicity 
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in tumour cells. The example comparator data presented in Table 1 is a strong indicator of the variation 
in results due to incubation time which may be related to solubility and could be affected by the media 
used. Compounds 1-4 show less potent cytotoxicity profiles, particularly in comparison with METVAN. 
A more comprehensive investigation to demonstrate cellular uptake properties and potential effect on 
other biological targets (e.g. protein binding) are required to better understand their properties and how 
they can be modified. It is likely that the complexes would be safe to administer in vivo, if evidence of 
efficacy was obtained.  This study indicates that the compounds are not suitable for application as 
cytotoxic drugs against U87/ glioblastoma cancer, but it is possible that they could have other anti-
tumour properties.  
 
Complex CC50 (μM)  72 h 
U87 cells [31] 
CC50 (μM) 24 h 
CHO-K1 cells 
[30,32] 
CC50 (μM) 72 h 
BALB/3T3 cells 
[33] 
1 94 - - 
2 57 - -    
3 126  - - 
4 62    - - 
METVAN 2.1/ 16* - - 
(A)VO3† - ≈100         ≈5    
VOSO4 - ≈100   ≈6 
Table 1 – CC50 (μM) values of the VO complexes synthesised compared to literature data. [29-33] 





Elemental analyses were carried out at the University of Hull. Infrared spectra were recorded on a 
Nicolet iS5 FT-IR spectrometer. Mass spectra were obtained from the EPSRC National Mass 
Spectrometry Service Unit, Swansea. Compounds L2H4, L3H2, L4H2 and [VO(acac)2] and 1 were 
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prepared using the previously reported methods. [23, 34-36] [VOCl3], [VOSO4] and L1H3 were 
obtained from Sigma-Aldrich Company Ltd. and were used as received.  
 
3.2 Preparation of {[VO(acac)2(OEt)](VO)L2]}2 (2) 
To a stirred solution of oxidovanadium(IV) acetylacetonate (1.78 g, 6.7 mmol) in anhydrous toluene 
(50 mL) was added 6,6/-methylenebis(4-(tert-butyl)-2-(hydroxymethyl)phenol) (1.00 g, 2.7 mmol) in 
anhydrous toluene (10 mL). The resulting solution was refluxed for 48 h under an inert atmosphere 
(N2). The volatiles were removed in vacuo and the dark green residue was extracted with warm 
anhydrous ethanol (20 mL). The resulting warm solution was filtered, and then left to stand at ambient 
temperature to afford small green crystals over a period of several weeks (0.84 g, 24 %). Found: C, 
55.93; H, 6.05%. C60H80O18V4 requires: C, 55.73; H, 6.24%. MALDI-MS m/z 1292.12 [M+]. νmax/cm-
1 3398 (br), 2962 (m), 1648 (w), 1588 (w), 1553 (w), 1519 (s), 1458 (w), 1416 (m), 1371 (s), 1356 (s), 
1286 (m), 1259 (s), 1188 (w), 1088 (m), 1015 (s), 993 (s), 936 (m), 863 (m), 796 (s), 788 (s), 684 (s), 
658 (m).  
 
 
3.3 Preparation of [Et3NH][VO(OMe)L3]2 (3) 
To a stirred suspension of 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid (0.50 g, 1.3 
mmol) in anhydrous acetonitrile (10 mL) was added triethylamine (5 drops) followed by vanadium(V) 
oxychloride (0.15 mL, 1.6 mmol). The resulting solution was refluxed overnight under a nitrogen 
atmosphere. The volatiles were removed in vacuo and the remaining residue was extracted into 
anhydrous methanol (20 ml). Following removal of methanol, the residue was taken up in 
tetrahydrofuran (20 mL). This solution was filtered under an inert atmosphere and concentrated to ca. 
half its original volume. This solution was left to stand at -20 °C for 48 h upon which dark blue crystals 
formed (0.37 g, 65%). Found: C, 58.46; H, 5.41; N, 9.52%. C53H55N7O12V2 requires: C, 58.73; H, 5.11; 
N, 9.05%. MALDI-MS m/z 875.99 [M+]. νmax/cm-1 3411 (w, br), 2979 (w, br), 2605 (w, br), 2496 (w, 
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br),1769 (w), 1705 (m), 1600 (s), 1568 (m), 1527 (w), 1514 (w), 1476 (w), 1460 (s), 1397 (m), 1364 
(w), 1308 (m), 1265 (w), 1251 (w), 1150 (m), 1097 (w), 1088 (w), 1034 (s), 1015 (w), 981 (m), 959 (s), 
856 (s), 839 (w), 799 (m), 779 (w), 757 (s), 719 (m), 702 (m), 645 (w), 627 (w), 613 (w).  
 
 
3.4 Preparation of [Et3NH][VO(OMe)L4]2  (4) 
To a stirred suspension of 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzosulfonic acid (0.50 g, 
1.2 mmol) in anhydrous acetonitrile (10 mL) was added triethylamine (5 drops) followed by 
vanadium(V) oxychloride (0.14 mL, 1.4 mmol). The resulting solution was refluxed overnight under a 
nitrogen atmosphere. The volatiles were removed in vacuo and the remaining residue was extracted into 
anhydrous methanol (20 ml). Following removal of the methanol, the residue was taken up in 
tetrahydrofuran (20 mL). This solution was filtered and concentrated to ca. half its original volume. 
This solution was left to stand at -20°C for 48 h to afford a dark blue precipitate (0.32 g, 56%). Found: 
C, 52.00; H, 3.05; N, 8.46%. C40H26N6O12S2V2·1(C4H8O) requires: C, 51.77; H, 3.36; N, 8.23%. 
MALDI-MS m/z 948.03 [M+]. νmax/cm-1 3410 (w, br), 1599 (s), 1567 (m), 1526 (w), 1513 (w), 1497 
(w), 1478 (m), 1459 (s), 1450 (w), 1399 (m), 1357 (m), 1322 (w), 1302 (m), 1264 (w), 1251 (w), 1174 
(s), 1123 (s), 1101 (m), 1066 (w), 1032 (s), 1012 (s), 991 (w), 982 (m), 962 (s), 863 (s), 842 (m), 764 
(w), 750 (s), 731 (w), 717 (w), 705 (m), 698 (w), 651 (m), 633 (s), 619 (m). 
 
3.5 Preparation of [VO(OMe)L3]2 (5) 
To a stirred suspension of 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid (1.00 g, 2.6 
mmol) in anhydrous acetonitrile (25 mL) was added oxidovanadium(IV) sulfate (0.42 g, 2.6 mmol). The 
resulting solution was refluxed overnight under a nitrogen atmosphere. The volatiles were removed in 
vacuo and the remaining residue was extracted into anhydrous methanol (20 ml). Following removal of 
any remaining undissolved solid, the solution was concentrated to ca. 5 mL and a layer of anhydrous 
dichloromethane (5 mL) was added. The two layers were allowed to diffuse over several weeks yielding 
dark brown crystals (0.51 g, 42 %). Found: C, 56.42; H, 3.35; N, 8.98%. C44H32N6O12V2 requires: C, 
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56.30; H, 3.44; N, 8.95%. MALDI-MS m/z 938.22 [M+]. 1H (400 MHz; CD3CN) δ 10.55 – 8.30 (very 
broad s, 1H, CO2H), 8.24 (4 H, t), 7.98 (1 H, d), 7.73 (1 H, d), 7.65 (2 H, d), 7.56 (2 H, d), 7.51 (1 H, t), 
7.31-7.39 (2 H, m), 7.17 (1 H, t), 7.09 (1 H, t), 7.03 (1 H, t), 6.97 (1 H, d), 6.91 (1 H, d), 6.81 (3 H, t), 
6.63-6.71 (2 H, m), 6.58 (1 H, d) – all arylH (for expansion, see figure S6, ESI), 3.28 (6 H, s, OMe). 51V 
(105 MHz; D4-MeOH) δ-579.61 (d). 
 
 
3.6 Cytotoxicity studies 
 Human glioblastoma cell line (U87) from ATCC and grown in DMDM media. All the media 
were purchased from Lonza. Complete media was made by the addition of 10% (v/v) heat 
inactivated fetal bovine serum (FBS) (Biowest, France), 1% (v/v) penicillin and streptomycin (100 
units/ml) antibiotic. All the cell culture was maintained at 370C in a humidified, CO2 (5%) 
controlled atmosphere with sub culturing carried out every 2-3 days as appropriate. Cells were 
incubated with the compounds in a multi-well plate (triplicate) with at least eight different 
concentrations for 72 h before determining their mitochondrial based reduction of a tetrazolium dye 
(MTS) to a formazan product (490 nm).   
 
3.7 X-ray crystallography 
X-ray diffraction data were collected for 2 using a Stoe IPDS2 image plate diffractometers using Mo Kα 
radiation. The crystal was mounted at the end of a glass fibre and held at 150 K during data collection 
using an Oxford Cryosystems nitrogen gas cryostream. The structure was solved using Superflip [37] 
and refined against F2 using SHELXL-2014. [38] The crystal examined was weakly scattering but 
allowed definitive determination of the molecular arrangement.  
X-ray diffraction data for 3 and 5 were collected by the EPSRC Crystallography Service using a rotating 
anode source and Rigaku Saturn detector with samples held at 100 K in a cryostream. The structures 
were solved using SHELXT [38] and refined using SHELXL-2014.  
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X-ray crystallography 
Table 2. Crystal structure data for complexes 2, 3 and 5. 
Compound 2 3 5 
Formula C117H149.5O36V8 C55H57N7O15V2 C23H20N3O7V 
Formula weight 2539.38 1157.95 501.36 
Crystal system Monoclinic Monoclinic Triclinic 
Space group P21/m Pc P-1 
Unit cell 
dimensions   
 
a  (Å) 12.280(2) 9.4363(7) 9.2829(4) 
b  (Å) 34.344(6) 10.8679(8) 10.1708(4) 
c  (Å) 18.192(3) 26.8741(19) 12.4115(3) 
α (Å) 90.00 90.00 85.393(2) 
β (Å) 91.276(15) 97.559(3) 81.001(3) 
γ (Å) 90.00 90.00 72.752(4) 
V  (Å3) 7671.(2) 2732.1(3) 1104.64(7) 
Z 2 2 2 
Temperature (K) 293(2) 100(2) 100(2) 













θ (max) (°) 18.848 27.515 27.485 
Reflections 




reflections 5203 10578 
5022 
Rint 0.2150 0.0678 0.0494 
Number of 
parameters 758 714 
 
324 
R1 [F2 > 2σ(F2)] 0.0840 0.1113 0.0375 
wR2 (all data) 0.2014 0.2911 0.0931 
GOOF, S 0.695 1.081 1.015 
Largest 
difference peak 
and hole (e Å-3) 
0.336 and -0.241 1.345 and -1.415 
 
0.369 and -0.401 
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4. Conclusion  
In conclusion, we have synthesized and structurally characterised a series of high valent 
oxidovanadium complexes bearing either chelates derived hydroxymethyl/phenols or triazol pro-
ligands. EPR measurements were used to investigate the electronic interactions. Biological 
screening (cell viability assays) showed low cytotoxicity indicating application of these compounds 
to treatment of U87 human glioblastoma models is not appropriate. Further investigation of the 
factors that may be affecting this (including cellular uptake) and the screening of a wider range of 
cancer cell lines is required. The complexes may also be of relevance to other disease states in which 
vanadium complexes have been shown to be active, such as hypertension. 
 
Appendix A.  
Supplementary data CCDC 1875986-1875988 contains the supplementary crystallographic data for 
<yyy>. These data can be obtained free of charge 
viahttp://www.ccdc.cam.ac.uk/conts/retrieving.html, or from the Cambridge Crystallographic Data 
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